-+ 0.00%
-+ 0.00%
-+ 0.00%

Needham Maintains Buy on MapLight Therapeutics, Lowers Price Target to $43

Benzinga·08/31/2026 10:05:14
Listen to the news
Needham analyst Ami Fadia maintains MapLight Therapeutics (NASDAQ:MPLT) with a Buy and lowers the price target from $45 to $43.